Bayer to present Phase III REVEAL Iodine-124 Evuzamitide PET study
Bayer announced its Phase III REVEAL study using investigational PET radiotracer Iodine 124 Evuzamitide, presented as a late-breaker at ESC 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.